Companies / Traws Pharma, Inc. / Activity
Activity — Traws Pharma, Inc.
17 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Parker Charles Nolan Executive | Grant | Common Stock | $0 | +15K | 15,393 0.10% of shares | low |
| Apr 16, 2026 | Orbimed Advisors LLC 10% owner | Buy | Common Stock | $998.2K | +598K +98.71% | 1,203,250 7.94% of shares | high |
| Mar 8, 2026 | Parker Charles Nolan Executive | Grant | Stock Option (right to buy) | — | +105K | 104,544 0.69% of shares | low |
| Dec 12, 2025 | Parker Charles Nolan Executive | Grant | Stock Option (right to buy) | — | +62K | 61,571 0.41% of shares | low |
| Oct 12, 2025 | Parker Charles Nolan Executive | Grant | Stock Option (right to buy) | — | +32K | 32,406 0.21% of shares | low |
| Apr 16, 2026 | Orbimed Advisors LLC 10% owner | Buy | Series C Warrants (right to buy) | — | +1.8M | 1,793,187 11.84% of shares | low |
| Apr 16, 2026 | Orbimed Advisors LLC 10% owner | Buy | Series B Warrants (right to buy) | — | +598K | 597,729 3.95% of shares | low |
| Apr 16, 2026 | Orbimed Advisors LLC 10% owner | Buy | Series A Warrants (right to buy) | — | +598K | 597,729 3.95% of shares | low |
| Mar 8, 2026 | Shoemaker Mary Teresa Director | Grant | Stock Option (right to buy) | — | +33K | 33,435 0.22% of shares | low |
| Mar 8, 2026 | Dukes Iain D. CEO | Grant | Stock Option (right to buy) | — | +231K | 231,336 1.53% of shares | low |
| Mar 8, 2026 | Leaman John Harold Director | Grant | Stock Option (right to buy) | — | +33K | 33,435 0.22% of shares | low |
| Mar 8, 2026 | Cautreels Werner Director | Grant | Stock Option (right to buy) | — | +31K | 31,258 0.21% of shares | low |
| Mar 8, 2026 | Stover Jack E Director | Grant | Stock Option (right to buy) | — | +33K | 33,435 0.22% of shares | low |
| Mar 8, 2026 | Redfield Robert Executive | Grant | Stock Option (right to buy) | — | +109K | 108,854 0.72% of shares | low |
| Mar 8, 2026 | Pauza Charles David Executive | Grant | Stock Option (right to buy) | — | +118K | 118,367 0.78% of shares | low |
| Mar 8, 2026 | Savchuk Nikolay Executive | Grant | Stock Option (right to buy) | — | +97K | 96,899 0.64% of shares | low |
| Mar 8, 2026 | Clarke Trafford Director | Grant | Stock Option (right to buy) | — | +33K | 33,435 0.22% of shares | low |